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Brachyspira hampsonii has been an emerging cause of swine dysentery (SD) since the 
mid to late 2000’s. Before the isolation of B. hampsonii, Brachyspira hyodysenteriae was the 
thought to be the sole etiologic agent of swine dysentery and the primary cause of 
mucohemmorhagic diarrhea in pigs (MHD). Research has been performed examining both 
whole cell and engineered B. hyodysenteriae vaccines, but little to no research has been 
reported for B. hampsonii. Quantification of Brachyspira cultures has been determined by 
CFUs, PCR, and whole cell counts; however, these methods have not previously been 
compared within the same study. Limitations with CFU quantification due to the growth 
characteristics of Brachyspira spp. has also highlighted the need for alternate methods of 
viability assessment such as the 50% endpoint of hemolysis positive plates (HPP50) that is 
described herein. Further research is also needed to compare growth media and methods of 
Brachyspira cultivation in broth media, specifically. 
The first study in this thesis compared the virulence of four B. hampsonii isolates in 
eight-week-old pigs using a novel frozen broth inoculation method compared with a 
previously described fresh broth method. It was concluded that the fresh broth method 
produced earlier onset and a greater duration of MHD, although the frozen broth method did 
produce significant disease compared to the negative control pigs. The second study assessed 
the efficacy of two proteinase-K (PKT) digested prototype vaccines (one derived from B. 
hampsonii and one from B. hyodysenteriae) against a B. hampsonii challenge in 11-week-old 
pigs. This efficacy study showed a reduction in clinical days of SD and fecal shedding for the 
B. hampsonii vaccine (homologous challenge), but not the B. hyodysenteriae vaccine 
(heterologous challenge). These studies show the possibility of using a frozen broth method 
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for B. hampsonii challenge models as well as further confirming the need for species-specific 




CHAPTER 1. LITERATURE REVIEW 
Emergence and Characterization of Brachyspira hampsonii in North America 
 Swine dysentery (SD) is characterized by mucohemorrhagic diarrhea (MHD) and 
inflammation of the large intestine, most notably the spiral colon.1 This disease has had 
economic ramifications in the swine industry for decades and was first described in the 
United States (US) in 1921.2 The causative agent was not isolated and identified until 1971 
and was first named Treponema hyodysenteriae and later reclassified to the genus Serpula, 
then Serpulina, and presently as Brachyspira hyodysenteriae.1,3,4 
In 2008, strongly beta-hemolytic Brachyspira spp. were being isolated from 
diagnostic cases in the US with clinical and microscopic features of SD that were atypical or 
untypeable using routinely available diagnostic assays.5 Further molecular and biochemical 
analysis at the University of Minnesota revealed that these atypical and untypeable 
Brachyspira isolates were a novel species with two distinct clades.6 This putative agent of SD 
was named Brachyspira hampsonii after Dr. David Hampson of Murdoch University in 
recognition of his extensive contributions to the field.6 Recently, PCR analysis of archived 
case samples in Canada has provided evidence that B. hampsonii has been present in 
Canadian pigs as early as 2002.7 
Unlike B. hyodysenteriae, B. hampsonii isolates are indole negative and α-glucosidase 
negative. Further examination has noted that within B. hampsonii, the production of β-
glucosidase varies.6 In 2016, B. hampsonii was confirmed and validated as a separate species 
using genomic comparison.8 However, there still remains some debate on how isolates within 
the B. hampsonii species can be further divided for epidemiological analysis.8,9 
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 Both murine and porcine models have been utilized to confirm that isolates of B. 
hampsonii can produce clinical signs comparable to SD produced by classical strongly beta-
hemolytic isolates of B. hyodysenteriae; however, there appears to be strain to strain 
variability in pathogenicity.10-14 
 Studies have also been performed to further characterize distribution and 
physiological effects on pigs.13,15-17 While a majority of these studies have confirmed the 
pathogenic nature of B. hampsonii, an attenuated isolate of this species (KL-180) has also 
been identified that was recovered from waterfowl.18 Work is also being done to create an 
attenuated isolate by laboratory passage to use as a vaccine candidate, but has thus far been 
unsuccessful.19 Alongside attenuation, antimicrobial susceptibility evaluations have been 
performed.20-22 Comparison with B. hyodysenteriae indicates a similar susceptibility to 
tiamulin, but increased susceptibility to a number of other antimicrobials.20 
Geographic Distribution 
 Given the recent isolation and characterization of B. hampsonii, there is relatively 
little information on the distribution of this isolate around the globe. In 2012, Belgian pigs 
that were exported to Germany tested positive for B. hampsonii clade I isolates that were 99% 
similar to US strains KC35 and EB106 using nox gene sequences.23 In 2013, it was reported 
that gilts originating from the Czech Republic tested positive for a B. hampsonii clade I 
isolate that was 99% similar to the nox gene sequence of the Canadian strain B. hampsonii 
30599.24 B. hampsonii was isolated from fecal samples and spiral colon samples from a 
German pig herd that did not display SD in 2014.25 In two recent surveys, Australian and 
Swiss pig herds tested negative for B. hampsonii suggesting these regions may thus far be 
free of the agent. 26,27 In a survey of pig feces from diarrhea cases in sixteen US states, B. 
hyodysenteriae as B. hampsonii were isolated with similar frequency.28 
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Birds, specifically waterfowl, have been described as a potential vector of concern. In 
Canada, many weakly hemolytic Brachyspira spp. and one strongly beta-hemolytic B. 
hampsonii isolate were recovered from snow geese cloacal swabs from 2011.18 Pigs that were 
inoculated with the strongly beta-hemolytic (and β-glucosidase positive) isolate did not 
develop clinical signs more severe than watery feces over a 14 day period. In contrast, B. 
hampsonii was also isolated from graylag goose feces from northwestern Spain in 2013.29 
This isolate was reported to be strongly beta-hemolytic and β-glucosidase positive and, when 
inoculated into pigs in 2016, a few pigs developed mucoid and bloody diarrhea.30 
Additionally, one of the sentinel pigs, that was penned with the inoculated pigs, also 
developed bloody diarrhea indicating this isolate was capable of spreading among infected 
pigs.30 These results suggest strongly beta-hemolytic B. hampsonii isolates of avian origin 
may differ in virulence when inoculated in pigs relative to isolates originating from swine. 
In vivo Evaluations 
 The physiological effects of SD have been extensively evaluated in swine models. A 
study comparing pathological intestinal changes in B. hampsonii and B. hyodysenteriae 
challenged pigs revealed no significant differences and concluded that both species are agents 
of swine dysentery.31 Changes in mucin expression were observed in both challenge groups 
when compared to the sham-inoculated pigs. A significant decrease in MUC4 expression and 
a concurrent increase in MUC5AC in the goblet cells of the apex spiral colon was observed in 
both Brachyspira challenge groups. The microbiota of B. hampsonii challenged-pigs has been 
evaluated15 and revealed that, alongside the development of MHD, the fecal microbiota has 
significant changes in microbe density and population ratios. Furthermore, Campylobacter 
and Desulfovibrio spp. were differential features in the microbiota of mucosal scrapings from 
pigs with SD in a recent study when compared with inoculated pigs that did not develop 
disease; whereas, Lactobacillus and Bifidobacterium spp. were differential features in those 
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pigs that did not develop disease.16 These findings further support the role of the microbiota 
in disease expression in pigs following infection with strongly beta-hemolytic Brachyspira 
spp. 
With investigations into the physiological mechanism of various Brachyspira spp. 
infections, the question of how diet may play a role in SD susceptibility in pigs led to 
numerous in vivo studies. While a majority of these studies evaluate B. hyodysenteriae, they 
provide a good indication of how B. hampsonii infections might be affected. When a diet 
including 30% distillers dried grains with solubles (DDGS) was compared with a diet 
including no DDGS, a shorter onset of clinical signs from time of Brachyspira challenges, B. 
hampsonii included, was observed.31 This was in agreement with a later study that confirmed 
increasing the insoluble fiber in the diet affects the intestinal microbiome and could increase 
susceptibility to Brachyspira infection.32 In an earlier study, a diet of cooked rice and animal 
protein showed protection from SD when challenged with B. hyodysenteriae and suggested 
that diet digestibility played a role in susceptibility to Brachyspira infection.33 In this study, 
pigs were assigned one of four diets: the cooked rice with lupin, wheat with lupin, and wheat 
with animal proteins groups all displayed SD in contrast to the rice with animal protein. The 
lack of protection from developing SD when fed a diet with lupins was also noted in a later 
pig model, while inulin inclusion was found to provide protection.34 In another study, 
however, a cooked rice diet provided no protection from SD when compared with a 
commercial barley/soybean diet and challenge with B. hyodysenteraie.35 The dietary effect on 
the development of SD appears to be multifactorial and heavily influenced by the 
composition, solubility, and inclusion rate of dietary fiber. With these studies in mind, diet 
should be considered when planning Brachyspira swine models. 
Mouse models have been used to screen the potential pathogenicity of Brachyspira 
isolates, but only three studies have evaluated B. hampsonii. Cecal mucus and neutrophilic 
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inflammation are the typical effect of a virulent Brachyspira challenge model in mice.10 In a 
study where mice were challenged with one of three B. hampsonii 30446 isolates that 
originated from Iowa, only one isolate colonized the mice. This isolate also caused notable 
cecal inflammation, even compared to the B. hyodysenteriae isolates in the study.10 Another 
study compared the clinical signs in two strains of mice (CF-1 and C3H) and two different 
diets when challenged with B. hampsonii 30446 isolated from a pig displaying MHD.36 This 
was done in order to provide a mouse challenge model that would provide more severe fecal 
scores and lesions. The CF-1 mice and low-zinc diet challenge models produced more severe 
clinical signs than the C3H mouse strain or the regular mouse feed. Lesion development was 
not consistent, however. A B. hampsonii 30446 isolate that was serially passaged in media 
100 times was compared to the original isolate in a mouse model.19 After being re-isolated 
from the least clinical mouse in the first experiment, additional mice were challenged to 
determine if the isolate’s pathogenicity was affected by the mouse passage. Neither the in 
vitro nor the additional mouse passage appeared to affect the pathogenicity of this isolate in 
mice, indicating that different methods may need to be explored to attenuate B. hampsonii.19 
Work on developing a Brachyspira vaccine has been ongoing, but the focus has been 
on B. hyodysenteriae. An inactivated, whole-cell B. hyodysenteriae vaccine that was 
adjuvanted and administered by intramuscular (i.m.) injection has been described.37 Two 
studies were conducted with a two-dose and three-dose vaccine regimen prior to challenge. In 
both studies, fewer vaccinated pigs developed swine dysentery than the unvaccinated pigs. 
An IgG ELISA performed on serum displayed an early immune response in the vaccinate 
pigs suggesting the efficacious response was due to the vaccine. Cellular immune response in 
pigs to sonicated whole cell and proteinase-digested B. hyodysenteriae antigen administered 
by i.m. injection have been noted in two other studies.38,39 A comparable cellular immune 
response was noted for both the sonicated and digested vaccines. A notable difference in 
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response with adjuvant inclusion was not definitive. Further investigation from these studies 
noted both a systemic and a site-specific mucosal immune response to the proteinase-digested 
antigen. Another study attempted to vaccinate pigs using immunogenic proteins to B. 
hyodysenteriae.40 An immune response to these proteins was confirmed, and following a B. 
hyodysenteriae challenge, fewer pigs that were vaccinated developed swine dysentery. The 
differences seen between the vaccinated and control groups were not statistically significant, 
however, so further work is needed with larger sample sizes to confirm if this vaccine 
response is repeatable. 
Without an available vaccine, other interventions for B. hampsonii infection need to 
be investigated. In B. hampsonii-challenged pigs, two therapeutic levels (0.006% and 
0.018%) of the antibiotic tiamulin resolved clinical disease and shedding.22 These results 
were comparable to the effects on pigs challenged with B. hyodysenteriae. B. hampsonii that 
was isolated from snow geese in Canada colonized but did not produce SD in pigs confirming 
variability in pathogenicity of field isolates.18 Shedding was confirmed with plate culture and 
PCR positive fecal and colon samples, but no gross or microscopic lesions significantly 
different from the control group were reported. Watery feces was the most severe clinical 
sign noted, and was also seen in the control group. B. hampsonii that are isolated from both 
birds and asymptomatic pigs could be investigated as potential vaccine candidates along with 
lab attenuation. 
Diagnostic Evaluations 
 Both culture and PCR assays have been used in animal studies to determine B. 
hampsonii presence in fecal and tissue samples.10-14,18,36,41,42 The specificity of PCR assays 
has been challenged with one study finding B. hampsonii isolates of avian origin confirmed 
by MLST creating false positives in B. hyodysenteriae, B. intermedia, and B. innocens/B. 
murdochii specific PCR assays.42 These assays used 23S, nox, and tylA as the target genes. 
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PCR has also been found to be less sensitive than culture evaluation of clinical samples in a 
swine challenge study.11 Challenge material for these animal studies have been quantified 
either by estimated CFUs or qPCR.14 There has been no known publication of the comparison 
between these two methods. It would be beneficial to conduct comparisons between a method 
that quantifies the viable Brachyspira in an inoculum culture with the qPCR method to better 
translate the published information. 
 A detailed comparison of matrix-assisted laser desorption ionization time-of-flight 
mass spectrometry (MALDI-TOF MS) and nox PCR methods has found them comparable in 
accuracy to the species level for B. hampsonii.43 The same evaluation cautioned at the 
accuracy of using this method for clade identification of B. hampsonii; however, clade 
determination is not routinely needed or desired in a diagnostic setting. In a recently 
published study, MALDI-TOF MS was used to confirm the species from rectal samples that 
were culture positive for Brachyspira and this method is now commonly used for routine 
speciation of primary cultures of Brachyspira from swine samples at many veterinary 
diagnostic laboratories.44 
In both mouse and pig models, histological evaluations of cecal and spiral colon 
sections, respectively, have been utilized to determine microscopic lesions and inflammation 
that could indicate Brachyspira infection.10,12-14,18,36,41 Warthin-Starry silver staining has been 
used historically to visualize spirochetes with morphology typical of Brachyspira spp. within 
lesions; however, this method lacks specificity to differentiate among Brachyspira spp. In 
one pig study, histological evaluations on colon sections of pigs challenged with B. 
hampsonii KL-180 were negative for spirochetes even though these samples were positive by 
culture plates and PCR for the isolate revealing limitations in the diagnostic sensitivity of 
direct detection methods given the limited amount of tissue examined in paraffin-embedded 
sections.18 Fluorescent in situ hybridization (FISH) has been found to successfully identify 
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Brachyspira from fixed pig colons as B. hampsonii using the Hamp1210 probe.45 Of all the 
samples evaluated, only one sample (B. intermedia fixed tissue) was found falsely positive by 
the Hamp1210 probe confirming adequate specificity for this probe. Probes for B. 
hyodysenteriae and B. hampsonii have also been used to detect these agents directly in fecal 
samples albeit with lower sensitivity than culture or PCR.46 
Recently, a B. hampsonii in vitro infection evaluation was performed using colon 
explants, which suggests there may be an additional model to assess potential pathogenicity 
of isolates.16 This method of Brachyspira evaluation could be a bridge in the future between 
in culture evaluation and mouse or pig studies. As more isolates are evaluated, pathogenicity 
profiles can be compared to genetic profiles which can also decrease the need for initial 
animal models if specific genetic markers of virulence are identified. For the moment, animal 
models are the most useful method to evaluate pathogenicity of Brachyspira isolates. 
The work described herein will examine B. hampsonii challenge and vaccine efficacy 
models in pigs. 
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CHAPTER 2. EVALUATION OF BRACHYSPIRA HAMPSONII ISOLATES FOR THE 
CAPACITY TO INDUCE SWINE DYSENTERY. 
Introduction 
This study was performed to evaluate the pathogenicity of B. hampsonii isolates in order 
to determine the best strain to use as the challenge isolate in a vaccine efficacy study. Four B. 
hampsonii isolates were evaluated (30446, 30599, C1257-109, and ST.288). For a direct 
comparison of two different inoculum preparation methods, an isolate of a strain previously 
reported for its virulence (30446) was administered using both a previously reported fresh broth 
method12 and an experimental media that was stored frozen until challenge. B. hampsonii 30599 
has also been reported to produce mucohemorrhagic diarrhea (MHD) following experimental 
inoculation.14 Two additional isolates (ST.288 and C1257-109) were evaluated because their 
nucleotide identities to either of the B. hampsonii 30446 or 30599 strains were unknown. These 
isolates were included in order to evaluate pathogenicity as they had been obtained from pigs 
with clinical signs of swine dysentery. This study will show a comparison of two field isolates 
with the published, virulent 30446 and 30599 strains, as well as look into a novel quantification 
method for Brachyspira inocula. 
This animal challenge model used was similar to the one reported in the previous 30446 
and 30599 evaluations.12,14 Pigs were within one week of the age at challenge compared to these 
previous studies; however, the current study retained the pigs for approximately two weeks 
longer prior to necropsy. The pigs were also challenged with an approximately 100-fold higher 
dose of challenge material; however, the viable bacteria in those doses was similar to what was 
referenced as a target in the original models. 
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Both fresh and frozen growth methods were evaluated on strain 30446 to determine if the 
frozen material was comparable to the fresh material in producing swine dysentery in pigs. Other 
strains were tested using the frozen method to determine if they performed better than the frozen 
30446 preparation. The overall hypothesis was that the frozen preparation would perform as well 
as the fresh method in producing clinical signs in pigs. 
Materials and Methods 
Preparation of inocula 
Challenge materials were prepared by one of two methods. Method 1 (BIVI) utilized an 
experimental broth medium and Method 2 (JBS) was consistent with a previously described broth 
medium.2 
For the BIVI method, the medium was generated by mixing Bacto™ Porcine Brain Heart 
Infusion (BHI) powder with GenPure™ water (37 grams and 1 Liter, respectively). The mixture 
was autoclaved on a liquid 15 minute cycle. After autoclaving, the mixture was cooled in a 
biosafety cabinet. The final growth medium was made by adding Fetal Bovine Serum (FBS) (10% 
final concentration) and a filter-sterilized 50% D-glucose solution (0.2% final concentration). 
Approximately 400 mL of growth medium was added to a 1 Liter glass bottle and inoculated with 
1 mL of the appropriate thawed glycerol stock (30446 = 7.95 Log10/mL; 30599 = 8.55 Log10/mL; 
C1257-109 = 8.43 Log10/mL; ST.288 = 8.50 Log10/mL) in Porcine BHI media with 0.2% D-
glucose, and 10% glycerol. After inoculation, the bottle was covered with Bio-Shield® sterilization 
wrap and incubated in a large anaerobic jar at 37°C shaking at 110 rpm in an Innova®44 incubator. 
After two days of incubation, each culture was monitored for growth by turbidity and spirochete 
presence on wet mount and 45mL of this culture was used to inoculate each of eight1 Liter glass 
bottles to produce 450 mL of final growth media that were incubated in a similar fashion to the 
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previous culture for one day. After growth, the eight bottles were pooled in a ten Liter Biotainer™. 
Amresco® glycerol (10% final concentration) was added to the pooled culture. The culture was 
mixed with a stir bar and dispensed in 100 mL aliquots using a peristaltic pump. These aliquots 
were frozen and stored in an ultra-low freezer (-70°C) until the day of challenge. 
For the JBS method, the medium was generated by mixing BBL™ Bovine Brain Heart 
Infusion (BHI) powder with GenPure™ water (37 grams and 1 Liter, respectively). The mixture 
was autoclaved on a liquid 15 minute cycle. After autoclaving, the mixture was cooled in a 
biosafety cabinet. The final growth medium (JBS broth) was made by adding Fetal Bovine Serum 
(FBS) (5% final concentration), defibrinated sheep blood (5% final concentration), and a filter-
sterilized 50% D-glucose solution (0.45% final concentration). Approximately 12 mL of growth 
medium was added to a 20x150mm glass tube along with a stir bar and inoculated with 1 mL of 
the appropriate thawed glycerol stock. After inoculation, the bottle was covered with Bio-Shield® 
sterilization wrap and incubated in a large anaerobic jar at 39°C while stirring. After one day of 
incubation, the culture was monitored for growth by turbidity and spirochete presence on wet 
mount, and approximately 12 mL was added to 132 mL of final growth medium in 250 mL glass 
bottle that was incubated in a similar fashion to the previous culture for one day. After one day of 
incubation, approximately 120 mL of this culture was added to 1.2 Liters of final growth medium 
in a 2.8 Liter, beveled flask and again incubated for one day. This material was administered fresh 
each day of challenge. 
Quantification of inocula 
Bacterial cell counts were performed using a Petroff Hausser counter from Hausser 
Scientific™. The challenge was diluted in 1X Phosphate-buffered saline (PBS). The coverslip 
was placed onto the counting chamber and 3 µL was loaded into the chamber. Under a darkfield 
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microscope the chamber was illuminated. Within the gridlines are 25 groups of 16 small squares. 
The total number of spirochetes (motile and nonmotile) were counted in five of the groups 
resulting in a total of 80 small squares. Duplicate counts were recorded with the average number 
of spirochetes counted per square determined. This value was multiplied by 2x107 (accounts for 
cell depth and cubic mm) and the culture dilution to determine the number of cell/ mL for each 
inoculum. No extraneous organisms were observed during these counts. 
HPP50 (Hemolysis Positive Plate50) counts were determined by performing triplicate 
serial ten-fold dilutions in 1X PBS on the challenge material. The dilutions from the appropriate 
range were triplicate plated (100 µl) and heavily streaked onto Thermo Scientific™ tryptone 
soya agar (TSA) with 5% defibrinated sheep blood agar plates. The plates were incubated 
anaerobically in anaerobic boxes using gaspaks and anaerobic indicators at 42ºC for six days. 
The plates were recorded as positive or negative for strong beta-hemolysis for each dilution 
plate. The Reed-Muench Method was used to calculate the 50% strong beta-hemolysis endpoint 
of the plates.(Ramakrishnan 2016) The final titers were reported in log10 format. 
Challenge material was extracted using the Qiagen DNeasy® Blood and Tissue kit per 
manufacturer’s instructions. Extracted samples were sent to the University of Saskatchewan for 

















0 8.25x107 5.62 x 107 3.93 x 108 
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0 2.57x107 2.14 x 107 1.27 x 108 
1 2.88x107 3.80 x 107 1.55 x108 





0 7.94x107 3.16 x 107 3.89 x 108 
1 8.31x107 5.62 x 107 2.00 x 108 
2 8.00x107 2.14 x 107 *1.15 x 108 
6 JBS Broth 
0 - - "Not Detected" 
1 - - "Not Detected" 
2 - - "Not Detected" 
*Trace amounts of B. hampsonii CladeII were detected [<10 GE/mL]. Challenge materials were screened for both 
Clade I and II nox PCR. 
Study design 
The animal inoculation experiment was performed at Veterinary Resources, Inc., Ames, 
IA and the study met all criteria for their IACUC approval. Sixty approximately six-week-old 
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pigs arrived on site on Day -14 and were randomly assigned to groups and blocked by litter by a 
BIVI statistician using SAS (version 9.4) prior to Day 0. All pigs were weighed on Day -1 and 
on the day of necropsy (Day 21 [groups 1, 2, 3, 5] or Day 28 [groups 4 and 6]). All pigs were 
vaccinated with Enterisol® Ileitis and Enterisol® Salmonella T/C on Day -13. The pigs were 
housed in a conventional ABSL-1 research facility, with empty pens separating groups. The 
groups were kept in separate pens for the duration of the study. The floors were slatted with a 
sheet of plywood covering one corner of each pen. The pigs were fed a non-medicated, pelleted 
soy/corn meal based feed. 
Clinical observations were conducted daily starting at Day -1 until necropsy. The focus of 
the observations was behavior and fecal consistency. Feces from individual pigs were scored 1, 
2, 3, or 4 to coincide with “0/Normal” (solid), “1/Diarrhea”, “2/Diarrhea containing mucus”, 
“3/Diarrhea containing blood”, or “4/Diarrhea containing mucus and blood” (MHD). Behavior 
was scored as “0/Normal”, “1/Abnormal” (aggressive physical stimulation required before pig 
rose), or “2/Dead”. On Day -13, -1, 14, and prior to euthanasia (Day 21 or 28), blood samples 
were collected from each pig for retention. 
On Study Day 0, 10 approximately eight-week-old pigs per group were fasted beginning 
8:00 PM-9:00 PM the evening prior to each challenge. The animals were fed a daily ration in the 
afternoon after challenge on Day 0 and Day 1 challenge and normal feeding resumed in the 
afternoon of the last day of challenge. All challenges were administered intragastrically (i.g.) 
using an 18 Fr. gastric tube. Starting on Day 0, the cleaning of the pens was limited to shoveling 
within the pen and water clean-up below the grate. No water clean-up was used on the pen itself 
for the duration of the study. 
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Isolate 30446 challenge material was prepared using the JBS Method and was generated 
on the days of challenge and administered fresh as described above. Purity and titer results were 
available following challenge. Due to a calculation error, only 0.45% glucose, roughly half 
originally planned, was included in the JBS media. Challenge material was also generated from 
isolates 30446, 30599, C1257-109, and ST.288 using the BIVI Method that were frozen upon 
harvest and then thawed on the day of challenge. The purity and titer of the frozen challenge 
stocks were determined prior to challenge as described above. On Day 0, Day 1, and Day 2 of 
the study, pigs were inoculated with 100 mL of the respective B. hampsonii culture; the control 
group received non-inoculated JBS broth. The target dose was 1x 107 bacteria per mL or 1x109 
bacteria in a 100 mL dose for all groups. The target doses were met or exceeded for all groups 
and days with the exception of Group 1 (study day 2: 5.6x106 bacteria per mL). A post-challenge 
titration was performed for each inoculation on each day using HPP50 and Petroff-Hausser 
counts. Additionally, the challenge was quantified at the University of Saskatchewan by 
qPCR.12,14 All challenge lots were found to be pure based on blood agar plate testing on the day 
of challenge. A summary of the study design is presented in Table 2.2. 
Table 2.2 Study design 
Group Challenge Material 
Days of 




B. hampsonii 30446, JBS growth method, 
fresh 
0, 1, 2 
5.62 x 109, 
5.24 x 109, 
5.62 x 108 
10 21 
2 
B. hampsonii 30446, BIVI growth 
method, frozen prior to challenge 
1.20 x 1010, 
6.76 x 109, 
2.14 x 109 
10 21 
3 
B. hampsonii 30599-BIVI growth method, 
frozen prior to challenge 
8.32 x 109, 
1.20 x 1010, 
1.20 x 1010 
10 21 
4 
B. hampsonii C1257-109-BIVI growth 
method, frozen prior to challenge 
2.14 x 109, 
3.80 x 109, 
4.68 x 109 
10 28 
5 
B. hampsonii ST.288- BIVI growth 
method, frozen prior to challenge 
3.16 x 109, 
5.62 x 109, 
2.14 x 109 
10 21 
6 Non-inoculated JBS broth - 10 28 
*Groups in which the majority of pigs had shown/were showing MHD were necropsied on Day 21 with the 
remaining groups necropsied on Day 28. 
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Two dry fecal swab samples were collected on Day -7, Day 0 prior to challenge, and Day 
5 from all pigs. Two dry fecal swabs were also collected from each pig presenting MHD 
approximately every three days until necropsy and from all pigs prior to euthanasia. All dry fecal 
swabs were cultured for Brachyspira using a CV2SR plate (TSA/5% sheep blood agar with 
colistin, vancomycin, spectinomycin, spiramycin and rifampicin) provided by the ISU-VDL. 
CV2SR plates were incubated anaerobically as described for the TSA plates above. Plates were 
read three times over a six to seven day incubation. Positive weakly beta-hemolytic Brachyspira 
cultures from Day -7 and 0 were analyzed by MALDI-TOF MS. The first and last strongly beta-
hemolytic Brachyspira positive cultures from any given pig were confirmed by MALDI-TOF 
MS. Fecal samples collected on Day 0, prior to challenge, and at necropsy (Day 21 or 28) were 
also screened by direct culture for Salmonella species using Remel™ xylose lysine deoxycholate 
(XLD) agar plates. XLD plates were incubated aerobically at 37ºC in ambient atmosphere and 
read at approximately 24 hours. 
During necropsy, the duodenum, jejunum, ileum, cecum, and spiral colon were examined 
for lesions of enteric disease. The cecum and spiral colon were specifically examined for lesions 
typical of swine dysentery such as hyperemia, inflammation, hypersecretion of mucus, mucosal 
hemorrhage, erosions, and ulcerations. The lesions observed in the cecum and colon were 
described and scored “0/Normal” (no signs of B. hampsonii associated lesions), “1/Showing mild 
lesions” (hyperemia, mucus, fibrin, and patchy ulceration), “2/Showing moderate lesions” 
(mucus, fibrin, hemorrhage, ulceration, multifocal colitis) or “3/Showing severe lesions” 
(extensive and severe mucohemorrhagic colitis with fibrin and necrosis), respectively. The intact 
colon was also examined for the presence of mesocolonic edema. Three representative sections 
of the spiral colon were collected for histopathological analysis and submitted to the ISU-VDL. 
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A section of fresh spiral colon (apex) was collected for Brachyspira culture with positive 
cultures being analyzed by MALDI-TOF MS and nox gene PCR and sequencing at the ISU-
VDL.11,43 These tissue samples were tested for Brachyspira species by culture using a CV2SR 
plate and screened by direct culture for Salmonella species using XLD agar plates as described 
above. Additional assessment was performed on the fixed colon tissues using routine 
histopathological analysis to detect signs of suppurative inflammation, necrosis, and spirochete 
presence at ISU-VDL. Sections were fixed in formalin for at least 24 hours prior to routine 
processing for histopathological. Serial sections were prepared and stained using hematoxylin 
and eosin as well as Warthin-Starry silver staining for spirochetes.  
 Suppurative Inflammation was scored as “0/None” (no neutrophilic infiltrates 
identified), “1/Mild” (multifocal infiltrates of less than 10 neutrophils each), “2/Moderate” 
(multifocal infiltrates of 10–20 neutrophils each), “3/Severe” (multifocal infiltrates of greater 
than 20 neutrophils each). Necrosis was scored as “0/None” (no epithelial necrosis observed), 
“1/Mild” (multifocal necrosis spanning less than 3 crypts), “2/Moderate” (necrosis spanning 3–5 
crypts), “3/Severe” (necrosis spanning more than 5 crypts). Spirochete presence was scored as 
“0/None” (none), “1/Low” (rare crypts containing low numbers of spirochetes), “2/Moderate” 
(multifocal crypts containing moderate numbers of spirochetes), “3/High” (numerous crypts 
containing high numbers of spirochetes often within enterocyte and goblet cells).  
Statistical analyses 
 Analyses were performed using JMP® Pro 14. ADWG and consecutive and total days of 
both abnormal behavior and mucohemorrhagic diarrhea were compared by group using a one-
way analysis of variance, with a Tukey-Kramer adjustment. Lesion, necrosis, and inflammation 
presence and severity as well as levels of spirochete presence in the spiral colon was also 
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evaluated using a Fisher’s Exact Test. Presence or absence of mesocolonic edema and results of 
fecal and spiral colon bacterial cultures were assessed using a Fisher’s Exact Test. Further fecal 
shedding comparisons were not evaluated by statistical analysis due to variation in sampling 
days between pigs. With all the analyses, p<0.05 values were considered significant. 
Results 
Clinical results 
Average daily weight gains (ADWG) were calculated over the challenge period (Figure 
2.1). All challenge groups, with the exception of Group 4-ST.288, had numerically lower 
ADWGs than Group 6-JBS Broth. Group 1-B. hampsonii 30446 (JBS) had the lowest ADWG of 
all groups. Both Groups 1 and 2 had significantly lower ADWG than Group 6 (p<0.0001 and 
p=0.0063). Group 1 ADWG was also significantly lower than Groups 3 through 5 (p=0.0078, 
p<0.0001, p=0.0003). Group 2 was also significantly lower than Group 4 (p=0.0018). Pigs were 
observed once daily for clinical signs indicative of B. hampsonii-associated disease starting at 
Day -1 until the end of the study. Behavior is summarized in Figures 2.2, 2.3, and 2.4. Group 1 
had the highest percentage of pigs showing abnormal behavior at least one day throughout the 
study (100%). Abnormal behavior was displayed on at least one day by 80% of pigs in Group 2, 
70% of pigs in Group 3, and 30% of pigs in Groups 4 and 5. One pig in Group 6 was noted for 
abnormal behavior on Day 20, but was noted for lameness as well. Groups 1 and 2 had 
significantly more consecutive days of abnormal behavior than Group 6 (p<0.0001 and 
p=0.0016) and all other study Groups. Group 1 had significantly more consecutive days of 
abnormal behavior than Group 2 as well (p=0.0214). Groups 1 and 2 also had a significantly 
greater number of total days of abnormal behavior than Group 6 (p<0.0001 and p=0.0013). 
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Group 1 also had significantly more total days of abnormal behavior than Groups 3-5. Group 2 
had significantly more total days of abnormal behavior than Groups 4 and 5. 
 
Figure 2.1. Average daily weight gain (ADWG) by group. 
 
 













































Figure 2.3. Consecutive abnormal behavior days by study group. 
 
 
Figure 2.4. Total abnormal behavior days by study group. 
 
In this study, the number of affected animals by day and group, the onset, and the 
duration of MHD varied by group. Details are provided in Figures 2.5-2.8 and Tables 2.3-2.4. 
Group 1 showed the earliest onset, the largest number of animals affected and the longest 
duration of all groups. No MHD was observed in the challenge control group (Group 6) or in any 
group prior to challenge. Only Groups 1 and 2 had a significantly greater number of consecutive 
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days and total days of MHD than Group 6 (p=0.0005 and p=0.0002), as well as Groups 4 and 5. 
Groups 1, 2, and 3 had significantly greater total days of MHD than Group 6 (p<0.0001, 
p=0.0002, p=0.0222). Groups 1 and 2 also had significantly greater total days of MHD than 
Groups 4 and 5. 
 
Figure 2.5. Group percentage abnormal fecal score by study day. 
 
 

















































































Group 1 Group 2 Group 3 Group 4 Group 5 Group 6
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Table 2.3. First MHD observation by group and number of animals affected 
Group Challenge 
First Study Day at which 
MHD was observed 
Number Pigs with 
≥1 Day of MHD 
1 B. hampsonii 30446 (JBS) 6 10a 
2 B. hampsonii 30446 (BIVI) 7 9a,c 
3 B. hampsonii 30599 (BIVI) 7 9a,c 
4 B. hampsonii C1257-109 (BIVI) 8 2b,d 
5 B. hampsonii ST.288 (BIVI) 10 6c,d 
6 JBS Broth - 0b 
Values connected by different letters are significantly different by Fisher’s Exact Test. 
 
Table 2.4. Consecutive days of MHD in individual pigs 
Group Challenge Number of Consecutive Days with MHD Observations 
  0 1 2 3 4 5 >5 
1 B. hampsonii 30446 (JBS) 0 0 0 0 6 1 3 
2 B. hampsonii 30446 (BIVI) 1 1 2 1 0 1 4 
3 B. hampsonii 30599 (BIVI) 1 3 0 0 3 2 1 
4 B. hampsonii C1257-109 (BIVI) 8 0 1 0 0 1 0 
5 B. hampsonii ST.288 (BIVI) 4 2 2 0 2 0 0 
6 JBS Broth 10 0 0 0 0 0 0 
 
 




Figure 2.8. Total MHD days by study group. 
 
Necropsy results 
Over 50% of the pigs in Groups 1, 2, 3, and 5 displayed MHD following challenge and 
were therefore necropsied on Day 21. Groups 4 and 6 were necropsied on Day 28. No gross 
lesions were observed in the duodenum, jejunum or ileum in any of the pigs. Groups 1, 2, 3, and 
5 had pigs with mild gross lesions in the cecum (20%, 10%, 10%, and 10% respectively). One 
animal in Groups 1 and 2 showed moderate cecal lesions. Two animals in Group 2 showed 
severe cecal lesions (20%). No cecal lesions were observed in Groups 4 and 6. Group 2 had 
significantly more severe gross cecal lesion scores than Groups 4 and 6 (p=0.0251 and 
p=0.0251). Cecal lesions are summarized in Table 2.5. Group 2 had significantly more pigs with 
any cecal gross lesions than Group 4 and 6 (p=0.0433). Groups 1, 2, 3 had significantly more 
pigs than Groups 4 and 6 with any spiral colon gross lesions of all sections. Group 5 only had 
significantly more pigs with gross lesions than Groups 4 and 6 for the proximal spiral colon 
section. Group 1 also had significantly more pigs with any apex gross lesions than Groups 5 
(p=0.0099) and 6 (p<0.0001), and distal gross lesions for Groups 3 (p=0.0286) and 5 (p=0.0099). 
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Group 2 had the highest percentage of pigs with severe gross lesions in all of the challenge 
groups across all of the spiral colon sections (Proximal: 30%; Apex 50%; Distal: 50%). Group 2 
had significantly more pigs with severe lesions than Groups 4 and 6 for apex and distal spiral 
colons (p=0.0163). Colonic lesions are summarized in Tables 2.6-2.8. 
Table 2.5. Cecal gross lesions by group 
Group Challenge 
Gross Lesions in Cecum by Animal1 
None Mild Moderate Severe 
1 B. hampsonii 30446 (JBS) 7a,b 2 1 0 
2 
B. hampsonii 30446 
(BIVI) 
6a 1 1 2 
3 
B. hampsonii 30599 
(BIVI) 
9a,b 1 0 0 
4 
B. hampsonii C1257-109 
(BIVI) 
10b 0 0 0 
5 
B. hampsonii ST.288 
(BIVI) 
9a,b 1 0 0 
6 JBS Broth 10b 0 0 0 
1Gross Lesions: “Normal/None” (no signs of B. hampsonii associated lesions), “Mild” (hyperemia, mucus, fibrin, 
and patchy ulceration), “Moderate” (mucus, fibrin, hemorrhage, ulceration, multifocal colitis) or “Severe” (extensive 
and severe mucohemorrhagic colitis with fibrin and necrosis); Values connected by different letters are significantly 
different. 
 
Table 2.6. Proximal spiral colon gross lesions by group 
Group Challenge 
Gross Lesions in Proximal Spiral Colon by Animal1 
None Mild Moderate Severe 
1 B. hampsonii 30446 (JBS) 3a 5 2 0 
2 B. hampsonii 30446 (BIVI) 5a 1 1 3 
3 B. hampsonii 30599 (BIVI) 6a 2 2 0 
4 
B. hampsonii C1257-109 
(BIVI) 
10b 0 0 0 
5 
B. hampsonii ST.288 
(BIVI) 
6a 3 1 0 
6 JBS Broth 10b 0 0 0 
1Gross Lesions: “Normal/None” (no signs of B. hampsonii associated lesions), “Mild” (hyperemia, mucus, fibrin, 
and patchy ulceration), “Moderate” (mucus, fibrin, hemorrhage, ulceration, multifocal colitis) or “Severe” (extensive 




Table 2.7. Apex spiral colon gross lesions by group 
Group Challenge 
Gross Lesions in Apex of Spiral Colon by Animal1 
None Mild Moderate Severe 
1 B. hampsonii 30446 (JBS) 1a 4 3 2a,b 
2 
B. hampsonii 30446 
(BIVI) 
3a,b 2 0 5a 
3 
B. hampsonii 30599 
(BIVI) 
5a,b 2 1 2a,b 
4 
B. hampsonii C1257-109 
(BIVI) 
10c 0 0 0b 
5 
B. hampsonii ST.288 
(BIVI) 
7b,c 0 2 1a,b 
6 JBS Broth 10c 0 0 0b 
1Gross Lesions: “Normal/None” (no signs of B. hampsonii associated lesions), “Mild” (hyperemia, mucus, fibrin, 
and patchy ulceration), “Moderate” (mucus, fibrin, hemorrhage, ulceration, multifocal colitis) or “Severe” (extensive 
and severe mucohemorrhagic colitis with fibrin and necrosis); Values connected by different letters in a column are 
significantly different. 
 
Table 2.8. Distal spiral colon gross lesions by group 
Group Challenge 
Gross Lesions in Distal Spiral Colon by Animal1 
None Mild Moderate Severe 
1 
B. hampsonii 30446 
(JBS) 
1a 5 3 1a,b 
2 
B. hampsonii 30446 
(BIVI) 
4a,b,d 1 0 5a 
3 
B. hampsonii 30599 
(BIVI) 




10c 0 0 0b 
5 
B. hampsonii ST.288 
(BIVI) 
7c,d 2 0 1a,b 
6 JBS Broth 10c 0 0 0b 
1Gross Lesions: “Normal/None” (no signs of B. hampsonii associated lesions), “Mild” (hyperemia, mucus, fibrin, 
and patchy ulceration), “Moderate” (mucus, fibrin, hemorrhage, ulceration, multifocal colitis) or “Severe” (extensive 





In Groups 1, 2, 3, 4, and 5, 20%, 40%, 20%, 0%, and 30% of pigs, respectively, displayed 
mesocolonic edema. None of the negative control pigs displayed mesocolonic edema. Group 2 
had significantly greater number of pigs with mesocolonic edema than Groups 4 and 6 (p=0.0433 
and p=0.0433). See Table 2.9 for details. 







1a,b B. hampsonii 30446 (JBS) 8 2 
2a B. hampsonii 30446 (BIVI) 6 4 
3a,b B. hampsonii 30599 (BIVI) 8 2 
4b B. hampsonii C1257-109 (BIVI) 10 0 
5a,b B. hampsonii ST.288 (BIVI) 7 3 
6b JBS Broth 10 0 
Values connected by different letters are significantly different. 
 
Diagnostic results 
One pig each from groups 1, 3, and 4 were fecal swab culture positive for Brachyspira 
murdochii by MALDI-TOF MS prior to challenge. These pigs were retained in the study.43 A 
different pig in Group 6 was spiral colon culture positive for B. murdochii by MALDI-TOF MS 
at the end of the study. All pigs were negative for Salmonella by fecal swab culture at Day 0. At 
necropsy, one pig from Groups 5 and 6 were positive for Salmonella group B; serotype 4, [5], 
12:i:-. Throughout the entire study 100% of pigs in Groups 1, 2, and 3 were culture positive for 
B. hampsonii for at least one fecal sample, results are summarized in Table 2.10. A majority of 
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pigs in Groups 4 and 5 (60% and 80%) were culture positive for B. hampsonii for at least one 
fecal sample, with Group 6 culture negative for all fecal samples throughout the study. Groups 1 
through 3 had significantly greater pigs that were fecal positive for strongly beta-hemolytic 
Brachyspira than Groups 4 (p=0.0433) and 6 (p<0.0001). All groups had significantly greater 
pigs that were spiral colon positive for strongly beta-hemolytic Brachyspira than Group 6. Group 
3 also had significantly more spiral colon positive pigs than Groups 4 (p=0.0054) and 5 
(p=0.0433). 











Pigs in Study 
(pos./total) 
MHD Pigs1 Positive at 
Necropsy by Fecal 
Sample 
(pos./MHD total) 
MHD Pigs1 Positive at 




B. hampsonii 30446 
(JBS) 
10/10a 8/10a,b,c 7/10 8/10 
2 
B. hampsonii 30446 
(BIVI) 
10/10a 9/10b,c 8/9 8/9 
3 
B. hampsonii 30599 
(BIVI) 




6/10b 4/10a 0/2 0/2 
5 
B. hampsonii ST.288 
(BIVI) 
8/10a,b 6/10a,b 3/6 5/6 
6 JBS Broth 0/10c 0/10d 0/0 0/0 
1Pigs that were ever positive for MHD throughout the study. Values connected by different letters in a column are 
significantly different. 
 
Histopathological evaluation of the spiral colon revealed the following: 70% of Group 1 
pigs showed severe suppurative inflammation, 100% of Group 3 pigs showed suppurative 
inflammation. There was no significance between groups for pigs with suppurative inflammation 
overall. All Groups other than Group 4 had significantly more pigs with any degree of necrosis 
than Group 6. Group 2 also had significantly greater pigs with necrosis than Group 4 (p=0.0115). 
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Group 2 also had significantly greater pigs with severe necrosis than 4 (p=0.0054), 5 (p=0.0286), 
and 6 (p=0.0054). Groups 1 through 3 had significantly more pigs positive for spirochetes by WS 
than Group 6 (p=0.0163, p=0.0004, p=0.0015). Group 2 also had significantly greater spirochete-
positive pigs than Groups 4 (p=0.0115) and 5 (p=0.0349), and 3 had significantly greater positive 
pigs than Group 4 (p=0.0349). Group 1 had significantly greater pigs with high spirochete presence 
than Groups 4 and 6 (p=0.0163). Group 2 had significantly greater high-spirochete pigs than Group 
3 (p=0.0349), and Groups 4 and 6 (p=0.0015). Sixty percent of the media control animals showed 
signs of mild suppurative inflammation and twenty percent had moderate inflammation; however, 
no pigs in the control group had severe suppurative inflammation as detected in Groups 1, 2, and 
3. See Table 2.11 for a detailed summary of the histopathological lesions and Table 2.12 for 
spirochete presence in colons. 




























1a 5 4 0 6a,b 2 1 1b 
6 JBS Broth 2a 6 2 0 10c 0 0 0b 
1Suppurative Inflammation: “0/None”  (no neutrophilic infiltrates identified), “1/Mild” (multifocal infiltrates of less 
than 10 neutrophils each), “2/Moderate”  (multifocal infiltrates of 10–20 neutrophils each), “3/Severe” (multifocal 
infiltrates of greater than 20 neutrophils each); 2Necrosis: “0/None” (no epithelial necrosis observed), “1/Mild” 
(multifocal necrosis spanning less than 3 crypts), “2/Moderate” (necrosis spanning 3–5 crypts), “3/Severe” (necrosis 
spanning more than 5 crypts); Values connected by different letters in a column are significantly different. 
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   None Low Moderate High 
1 
 B. hampsonii 
30446 (JBS) 
5a,b 0 0 5a,b 
2 
 B. hampsonii 
30446 (BIVI) 
2a 1 0 7a 
3 
 B. hampsonii 
30599 (BIVI) 
3a,c 1 4 2b,c 
4 
 B. hampsonii 
C1257-109 
(BIVI) 
8b,d 1 1 0c 
5 
 B. hampsonii 
ST.288 (BIVI) 
7b,c,d 0 0 3a,b,c 
6  JBS Broth 10d 0 0 0c 
1Spirochete Presence: “0/None” (none), “1/Low” (rare crypts containing low numbers of spirochetes), “2/Moderate” 
(multifocal crypts containing moderate numbers of spirochetes), “3/High” (numerous crypts containing high 




 This study was successful in comparing two different inoculum preparation methods for 
B. hampsonii 30446 and for assessing differences in pathogenicity of four different B. hampsonii 
strains from frozen inoculum administered to pigs. None of the negative control pigs were 
positive for B. hyodysenteriae or B. hampsonii or displayed MHD throughout the study. While 
Salmonella was recovered from four animals (two were excluded from the study prior to 
randomization), the data does not suggest that this finding significantly affected the outcome of 
the study: no MHD or cecal lesions, hallmarks of a Brachyspira infection, were observed in 
these animals. One pig was in the challenge control group and did not develop diarrhea 
throughout the study. The other pig was in Group 5 and developed diarrhea from Days 10-15. 
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Because most of the analysis was performed on MHD days, the possible affect this agent may 
have had was minimal. Additionally, three pigs from three different groups were fecal swab 
culture positive for B. murdochii by MALDI-TOF MS prior to challenge. These pigs were 
retained in the study. At the end of the study only one pig from a different group (negative 
control group) was spiral colon culture positive for B. murdochii by MALDI-TOF MS. Two of 
the three pigs displayed lower clinical signs, but were not unique in their group that either only 
had one pig display MHD throughout the study or several pigs display MHD one day throughout 
the study. The third pig displayed MHD comparable to the pigs in its group. 
When comparing all treatments, it can be concluded that the 30446 isolate grown in JBS 
and used as a fresh preparation, as previously described, resulted in the most virulent inoculum. 
The primary parameter for assessing the effect of each challenge preparation was the proportion 
of pigs demonstrating MHD. Group 1 was the only group in which all animals displayed MHD at 
some point following challenge. Group 1 also showed the longest duration of MHD with all pigs 
exhibiting clinical signs for at least four days. MHD was first observed in Group 1 pigs (Day 6) 
with 90% of pigs demonstrating MHD by Day 11. Group 1 also had the highest percentage of 
pigs with gross lesions in all three spiral colon sections. 
Group 2 pigs were infected with the same strain 30446 as Group 1, but the material was 
grown in BIVI media and frozen prior to use. While the Group 2 treatment yielded the highest 
percentage of pigs with mesocolonic edema (40%), the highest frequency of severe gross lesions 
in all sections of the spiral colon, the highest percentage of pigs with severe necrosis (60%) and 
the highest numbers of spirochetes in the crypts of the spiral colon (70%), the group did not 
show MHD at the frequency, duration and onset that was observed in Group 1. 
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A comparison of fresh vs. frozen and JBS vs. BIVI media as separate parameters is not 
possible based on the data generated in this study, as both variables were combined in Groups 1 
and 2. Based on the data obtained in this study, it is recommended to use freshly prepared isolate 
30446 material grown in JBS in future studies if the objective is to induce a severe challenge and 
a high percentage of pigs developing MHD in the positive challenge control group. 
However, using a fresh challenge preparation is not without drawbacks: a large volume of 
challenge has to be prepared on three consecutive days for traditional published models. This 
limits the maximum number of animals that can be enrolled in a study. In addition, the purity of 
the material and the titers are not known until several days after administration. It is therefore 
recommended to conduct an additional study in which the variables “media” and “fresh vs. 
frozen” are further examined. 
The remaining isolates tested, all grown in BIVI media and frozen following preparation, 
seemed to be less virulent than the 30446 and were not further considered as challenge isolates. 
30599 (used in Group 3) induced MHD in 90% of the animals which confirmed its virulence 
displayed in a previous study.1 A majority of the animals in Group 3 did not display gross 
lesions, even though the onset of MHD and number of consecutive days of MHD were 
comparable to Groups 1 and 2. With isolate C1257-109 (used in Group 4) only inducing MHD in 
20% of the challenged animals and failing to induce gross lesions in the spiral colon, it should 
rather be considered as a potential isolate for attenuation by in vitro passage. While focusing on 
sampling animals showing MHD, no solid conclusions could be drawn about the colonization 
and shedding characteristics of this isolate. However, the isolate was recovered in 40% of the 
apex spiral colon samples. In Group 5, Isolate ST.288 had a majority of pigs display at least one 
day of MHD, but six pigs in the group were ≤1 consecutive day of MHD throughout the 
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challenge period. ST.288 failed to generate gross lesions in a majority of pigs. With isolate 
ST.288 not being a contender as a challenge isolate, the fact that a B. hampsonii Clade II 
contamination was potentially identified by PCR in the Day 2 challenge for Group 5 becomes a 
finding of no consequence. 
All samples and data collected during this study were found to be valuable and should be 
collected in future studies. With 70% of Group 1 pigs still shedding at necropsy, the benefit of 
sampling more than twice a week following challenge should be considered. The finding that 
80% of the negative control pigs showed some degree of neutrophilic colitis demonstrates the 
importance of a control group in determining the amount of background inflammation created by 
other factors outside of Brachyspira infection. 
For future studies, until sufficient data is collected so that one quantification assay can be 
determined as superior, challenge materials should continue to be quantified using multiple 
methods as in this study. In general, it is deemed feasible to determine an assessment of viability 
of the inoculum using the HPP50. Despite using only half the glucose originally planned for the 
Group 1 challenge material, the challenge of the group appeared to be successful. No change will 
be made to the media recipe for future vaccine efficacy studies to limit study-to-study variation. 
However, in the vaccine efficacy study, culture collected for qPCR will be pelleted and stored at 
-20°C prior to DNA extraction to prevent DNA loss during the freeze-thaw-cycle.  
 In summary, the Group 1 B. hampsonii isolate and challenge preparation proved to be the 
most effective in inducing MHD, which was the primary parameter to assess the challenge in this 
study. Therefore, B. hampsonii 30446 with the JBS method for inoculum preparation was 
selected for use in the vaccine efficacy study (Chapter 3).  
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CHAPTER 3. EVALUATION OF BRACHYSPIRA PROTOTYPE VACCINES AGAINST 
A BRACHYSPIRA HAMPSONII CHALLENGE 
Introduction 
The objective of this study was to develop a vaccine to protect against swine dysentery. 
Brachyspira hyodysenteriae (B. hyodysenteriae) and Brachyspira hampsonii (B. hampsonii) are 
causative agents of swine dysentery, manifested as mucohemorrhagic diarrhea (MHD). 
In the previous chapter, four B. hampsonii isolates and two growth methods were 
evaluated in a challenge study in eight-week-old pigs. An isolate of B. hampsonii 30446 prepared 
fresh using JBS broth as previously described12 caused the most severe MHD in pigs and was 
chosen for this efficacy study as the challenge isolate and preparation method. 
Two Brachyspira vaccine prototypes that derived from a United States expired patent 
were evaluated against the B. hampsonii 30446 challenge:  B. hampsonii 30446 proteinase K 
treated (PKT) vaccine that is homologous with the challenge isolate and B. hyodysenteriae B204 
PKT vaccine that is a different species than the challenge to evaluate cross-protection. 
The efficacy of each vaccine was evaluated by the proportion of animals protected 
against MHD when compared to the challenge control animals. 
 
Material and Methods 
Preparation of vaccines and challenge inoculum 
To prepare the proteinase K treated vaccines, B. hampsonii 30446 and B. hyodysenteriae 
B204 cultures were propagated similar to the BIVI method described in Chapter 2. The 
proteinase K preparation was derived from a United States expired patent.44 These cultures were 
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concentrated by centrifugation and reconstituting the pellets 100X. The concentrated cultures 
were then treated with thimerosal 1:10,000 final concentration with shaking at 37°C for 48 
hours. The treated cultures were then washed in 1X Phosphate-buffered saline (PBS) and the 
spirochetes were lysed with a microfluidizer. The lysed preparations were treated with proteinase 
K solution (Promega, Cat#V3021) at a final concentration of 50µg/mL with incubation at 56°C 
for 2 hours, 37°C for 12 hours with shaking, and finally stored at -70°C until vaccination. A 
whole protein quantification was performed on the proteinase K vaccines prior to formulation 
using the Quant-IT™ Protein Assay Kit (Invitrogen, Cat#Q33210) per manufacturer’s 
instructions. On the days of vaccination, preparations were thawed in 37°C water baths and 
emulsified with Freund’s Incomplete Adjuvant (Colorado Serum Company, Cat#31451) using a 
1:3 ratio of adjuvant to bacterial digest. The pigs were vaccinated by i.m. injection on Day 0 and 
21 with 2.5mL/dose with a 1.5 mg/mL target. SDS-page protein gels were run using the 
NuPAGE™ system per manufacturer’s instructions. Approximately 16µg of B. hampsonii PKT 
and B. hyodysenteriae PKT pre-formulated preparations were loaded into each lane. All but one 
protein gel was transferred to nitrocellulose membrane using the iBlot 2 Dry Blotting System per 
manufacturer’s instructions. The remaining gel was stained using SimplyBlue SafeStain per 
manufacturer’s instructions. 
B. hampsonii 30446 JBS challenge material was generated and administered as described 
in Chapter 2. 
Quantification of the inoculum 
Bacterial cell counts and HPP50 counts were determined for the challenge material as 
described in Chapter 2. Challenge material was extracted using the Qiagen DNeasy® Blood and 
Tissue kit per manufacturer’s instructions. Extracted samples were sent to the University of 
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Saskatchewan for PCR quantification.12,14 See Table 3.1 for details regarding quantification of 
the inoculum. 
Table 3.1 Study design and challenge inocula titers 










































0, 21 2.5mL/i.m. 
3 14 Saline 0, 21 2mL/i.m. 
4 4 None - - None - - - 
*Pre-formulation protein quantification 883 µg/mL. 
**Pre-formulation protein quantification 814.5 µg/mL 
 
Study design 
Fifty-three approximately three-week-old pigs arrived on site three weeks prior to 
vaccination and were randomly assigned to groups and blocked by litter by a BIVI statistician 
using SAS (version 9.4). Fifteen pigs were assigned to each of the treatment groups with the strict 
controls having eight. The treatment table (3.1) lists the number of pigs enrolled in the study during 
the challenge phase due to losses during the vaccination phase. All pigs were screened prior to 
vaccination for both weakly beta-hemolytic and strongly beta-hemolytic Brachyspira and also 
Salmonella by culture as described in Chapter 2. All pigs were negative for Salmonella and 
strongly beta-hemolytic Brachyspira. Pig 113 (Group 1) was positive for a weakly beta-hemolytic 
Brachyspira prior to vaccination and in the spiral colon content at the conclusion of the study that 
was determined to be Brachyspira innocens (B. innocens) by MALDI TOF-MS.43 
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Pigs were housed in an ABSL2 research facility with empty pens separating groups. 
Groups 1-3 were housed in one room in separate pens during the vaccination phase, and 
were commingled during the challenge phase until the end of the study. The strict controls 
(Group 4) were housed in a separate room throughout the study. Animal pens consisted of open 
stainless steel gating on raised decks with slotted steel flooring. The pigs were fed the same non-
medicated, pelleted soy/corn meal based feed throughout the study that was used for the 
challenge study in Chapter 2. 
All pigs were vaccinated with Enterisol® Ileitis and Enterisol® Salmonella T/C prior to the 
start of the study. Due to respiratory concerns, pigs across all groups were administered Draxxin® 
on Day -8 and Day -5. All pigs in treatment groups were administered Excede® on Day 6 due to 
concerns of lethargy and wasting. 
On Day 0 and 21 (6 weeks old and 9 weeks old), Groups 1-3 were vaccinated i.m. with 
2.5mL of respective material described in Table 3.1. 
On Study Day 35, 36 and 37, eleven-week-old pigs in Groups 1-3 were challenged 
intragastrically (i.g.) with 100 mL of B. hampsonii 30446 broth culture followed by 50mL 1XPBS 
flush i.g using an 18 Fr. gastric tube. The pigs were fasted from the evening prior to each day of 
challenge with a daily ration fed each afternoon following challenge. Normal feeding regimen 
resumed on the afternoon of the last day of challenge. 
Weights were collected prior to vaccination and at necropsy. General observations and 
clinical observations were recorded throughout the study. Behavior was scored as either “normal” 
(0), “abnormal” (1) (lethargy that requires aggressive physical stimulation before pig will rise), or 
“dead” (2). The feces from individual pigs were scored for consistency: feces were scored as 
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“normal” (solid) (0), “wet cement/loose cow pie”(1), “diarrhea”(2), “diarrhea containing 
mucus”(3), “diarrhea containing blood”(4), or “diarrhea containing mucus and blood”(5). A 
behavior score of ≥1 and a fecal score of ≥2 were considered abnormal. 
Fecal swabs were collected throughout the study for fresh culture. All fecal samples were 
tested for Brachyspira species by culture using a CV2SR agar plate provided by the ISU-VDL. 
Fecal samples collected on Day 0, prior to challenge, and at necropsy were screened by direct 
culture for Salmonella species using Remel™ XLD agar plates. Plates were cultured using the 
same methods described in Chapter 2. 
Blood samples were collected D -9, D21 (prior to vaccination), D35 (challenge), and D62. 
At necropsy, the small and large intestines were grossly evaluated for lesions of enteric disease. 
The cecum and spiral colon tissue sections were described and scored as “normal” (no signs of B. 
hampsonii associated lesions), “mild lesions” (hyperemia, mucus, fibrin, and patchy [no defined 
borders] ulceration), “moderate lesions” (mucus, fibrin, hemorrhage, ulceration, multifocal colitis) 
or “severe lesions” (extensive and severe mucohemorrhagic colitis with fibrin and necrosis). The 
mesenteric lymph node size was also observed and recorded as "0/Normal" or "1/Abnormal-
Enlarged" for each pig; and any mesocolonic edema present was recorded. 
A representative section of the spiral colon (apex) was collected for culture. These tissue 
samples were tested for Brachyspira species using a CV2SR agar plate and screened by direct 
culture for Salmonella species using XLD agar plates as described above. Three representative 
sections (proximal, apex, and distal) of the spiral colon were also collected into 10% neutral-
buffered formalin for histopathological analysis and were submitted to the ISU-VDL for 
evaluation of suppurative inflammation, necrosis, and spirochete presence. Sections were fixed 
in formalin for at least 24 hours prior to routine processing for histopathological analysis. Serial 
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sections were prepared and stained using hematoxylin and eosin as well as Warthin-Starry silver 
staining for spirochetes.  
Statistical Analysis 
Statistical analysis was performed on the groups commingled during the challenge phase 
(1-3). Statistical analysis of data was conducted by a BIVI Statistician using SAS version 9.4 (SAS, 
Cary, North Carolina/USA, SAS Institute, Inc.). Summary statistics were generated as appropriate 
for the outcome. Fecal and behavior scores, necrosis, and results of bacterial culture were 
summarized using two methods: 1) the number of days exhibiting abnormal outcome and 2) the 
binary response of if the animal ever exhibited an abnormal outcome based on a score greater than 
“0” for behavior and greater than “1” for fecal scores. The total number of days exhibiting an 
abnormal outcome was analyzed using a generalized linear mixed model (GLMM) which included 
treatment group as a fixed effect, challenge room as a random effect and a Poisson distribution 
with a log link. The least squares estimate of the average number of days and confidence was 
reported for this method.  The stratified mitigated fraction (MF) was also performed to analyze 
this data. The observed MF was calculated along with a 95% bootstrap confidence interval. The 
stratification was based on challenge room. 
The binary response described above was analyzed using a GLMM with treatment group 
as a fixed effect, challenge room as a random effect and a binomial distribution with a logit link. 
The least squares estimate of the proportion, including a confidence interval, of animals with two 
or more days of abnormal clinical signs were reported. A prevented fraction analysis was also 
performed using the Cochran-Mantel-Haenszel method in SAS using PROC FREQ. The 
stratification variable for this analysis was challenge room. 
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The fecal and behavior scores were summarized using the number of days affected as 
described previously, but the binary outcome was calculated based on if the animal showed the 
clinical sign on two or more days, instead of a single positive event. 
An additional analysis for histopathological colonic necrosis and results of bacterial culture 
was performed using the binary outcome of ever affected or positive culture, respectively, in which 
the GLMM had treatment group and location as fixed effects, challenge room as a random effect 
and a binomial response with a logit link. The output for this analysis was the least squares estimate 
of the proportion of animals that had abnormal responses for each location alone with a lines 
display showing statistically significant differences. 
The person delivering the treatments was not the same person making the daily 
observations. Blinding during the vaccination phase for clinical observations was incomplete 
because the pigs were housed by group. Individuals making the clinical observations during the 
challenge phase were blinded because Groups 1-3 were commingled. Scientists conducting 
laboratory testing were blinded to group assignments for the entire study. 
Results 
Weights 
Weights were collected prior to vaccination and at necropsy. The average daily weight gain 
in kilograms was calculated for each pig. Statistical analysis was performed on Groups 1-3 due to 
the housing arrangement. There was no statistically significant difference between Groups 1-3. 





Table 3.2 ADWG(kg) 
Group Treatment 
Ave Daily Weight Gain per 
Group (Kg) Standard Error 
P-Value Difference from 
Control (Group 3) 
1 B. hampsonii 30446 PKT 0.90 (0.90) 0.04514 0.1911 
2 B. hyodysenteriae B204 PKT 0.85 (0.86) 0.04472 0.7413 
3 Challenge Control 0.84 (0.84) 0.04188 ∙ 
4 Strict Control 0.93 0.021733 ∙ 
() = LS Mean 
 
Observations 
Prior to Day 0, three pigs were euthanized due to health complications. Behavior and fecal 
scores were observed throughout the vaccination phase of the study. A majority of pigs in each 
group had no abnormal behavior scores during the vaccination phase. See Table 3.3 for the 
vaccination phase behavior scores. 
 
Table 3.3 Behavior observations post-vaccination  
Treatment Group Abnormal Behavior Scores (Vx Phase) 
 Total # of Pigs at Day 0 # Pigs ≥1 Day of Abnormal Behavior Scores 
1 11 4 
2 14 1 
3 14 5 
4 4 1 
 
No abnormal fecal scores were observed during the vaccination phase. Seven pigs were 
removed during the vaccination phase due to other complicating factors unrelated to vaccination. 
Pig 53 (Group 1) was removed from the study on Day 57 when it was found dead and is 
included in the analysis. This pig went into respiratory distress approximately 10-15 minutes post 
handling and after being observed normal. The final diagnosis was emphysema in lungs, 
myocardial degeneration/myocarditis, and passive congestion of liver/degeneration, which 
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supports poor myocardial function. These clinical signs were inconsistent with swine dysentery; 
the mortality was concluded to be unrelated to the Brachyspira challenge. Pigs were observed once 
daily for clinical signs indicative of B. hampsonii associated disease throughout the challenge 
phase of the study. Feces and behavior were scored daily as previously described. For behavior, 
there were significantly fewer days of abnormal behavior for Groups 1 and 2 when compared to 
Group 3 (Mantel-Haenszel Test, p = 0.0129 and p = 0.0043, respectively). Table 3.4 summarizes 
the days of abnormal behavior by group. 
 
Table 3.4 Behavior observations post-challenge 
Treatment 
Group Abnormal Behavior Scores (Challenge Phase) 
 Total # of 
Pigs Post-
Challenge 








1* 11 1 0.09 (0.07)a 0.08214 
2* 14 2 0.29 (0.19)a 0.1585 
3* 14 8 1.35 (1.00)b 0.7259 
4 4 0 0 - 
() = LS Mean; Values connected by different letters are significantly different 
 
For the proportion of pigs with two or more days of abnormal fecal scores (score greater 
than 1), Group 1 had significantly fewer pigs than Group 2 (Mantel-Haenszel Test, p = 0.0423). 
The frequency distribution of two or more days with abnormal fecal scores and abnormal fecal 












N % N % 
 
8 72.7 3a 27.3 11 
1* 
2* 4 28.6 10b 71.4 14 
3 9 64.3 5 35.7 14 
* = groups with statistical significance; Values connected by different letters are significantly different 
 
Table 3.6 Fecal observations post-challenge 
  












(score = 4) 
Ever had 
MHD 










B. hampsonii 30446 
PKT 




10/14 7/14 1/14 3/14 11/14 8/14 4 (4.00) b 
3* Challenge Control 8/14 5/14 0/14 0/14 11/14 5/14 2.21 (2.22) b 
4 Strict Control 0/4 0/4 0/4 0/4 0/4 0/4 0 
() = LS Mean; Values connected by different letters are significantly different 
When fecal scores were analyzed, Group 2 had significantly more abnormal days than 
Group 3, but also Group 1 (Mantel-Haenszel Test, p = 0.0126 and 0.0005 respectively). 
Serological analysis 
Western blot analysis was also performed on both proteinase K pre-formulated vaccine 
preparations. Prior to western blots, an SDS protein gel was performed to assess total protein 
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presence shown in Figure 3.1. The blots in Figure 4.2 show greater reactivity of the B. hampsonii 
PKT preparation than the B. hyodysenteriae PKT preparation to serum of B. hampsonii 
challenged pigs from Chapter 2 and in Group 3 pigs from the current study. A 35 kDa band in 
the western blots appears on the post-challenged serum blots for the B. hampsonii lane, but not in 
the pre-challenged blot (Figure 3.2a). This band also appears on the protein gel (Figure 3.1). A 
slight reaction in the B. hyodysenteriae lane in the western blots from Group 3 in this study can 
be noted between the pre and post-challenge serum (Figure 3.2b), and there is a slight band just 
under 60 kDa from the western blots of serum collected in Chapter 2 (Figure 3.2a). A very faint 
band just below 30kDa was also noted B. hyodysenteriae PKT in Figure 3.2b against the Day 62, 
B. hampsonii-challenged serum from this study. This band could not be seen in the protein gel, 
but was present in the B. hyodysenteriae PKT blots suggesting specificity. Western blots of 
pooled sera from Groups 1 and 2 (Figure 3.2c and 3.2d, respectively) both demonstrate that an 
immune response was elicited in the vaccine groups of this study against their respective PKT 
preparation. 
 
Figure 3.1. SDS Page protein gel. 




Figure 3.2. Western blots of PKT preparations. 
Ladder in kDa. a.) from left to right: Day -1, Day 14, and Day 21 serum pool from Group 1 of the challenge study 
(Chapter 2); Lane 1=B. hyodysenteriae PKT, Lane 2=B. hampsonii PKT, b.) from left to right: Day-9 and Day 62 
serum pool from Group 3 (non-vaccinated, challenged control) of the current study showing a similar increase in 
serum reactivity to the B. hampsonii PKT at the end of the study as observed in samples from Chapter 2; Lane 1=B. 
hyodysenteriae PKT, Lane 2=B. hampsonii PKT, c.) from left to right: Day-9, Day 21, and Day 33 serum pool from 
Group 1 of this study against B. hampsonii PKT, d.) from left to right: Day-9, Day 21, and Day 33 serum pool from 
Group 2 of this study against B. hyodysenteriae PKT. 
 
Necropsy 
One animal removed during the challenge period (D57) was necropsied in a similar manner 
as those necropsied on D63. There were no significant differences in the presence of gross lesions 




Table 3.7 Spiral colon gross lesions results by section and severity 
 
Group Treatment Gross Lesions1 
  
Prox SC Apex SC Distal SC 













12/14 2/14 0/14 0/14 11/14 1/14 2/14 0/14 12/14 2/14 0/14 0/14 
4 Strict Control 3/4 1/4 0/4 0/4 4/4 0/4 0/4 0/4 4/4 0/4 0/4 0/4 
1Gross Lesions: “Normal/None” (no signs of B. hampsonii associated lesions), “Mild” (hyperemia, mucus, fibrin, 
and patchy ulceration), “Moderate” (mucus, fibrin, hemorrhage, ulceration, multifocal colitis) or “Severe” (extensive 
and severe mucohemorrhagic colitis with fibrin and necrosis); Values connected by different letters in a column are 
significantly different. 
 
The proximal, apex, and distal sections of the spiral colon collected post-challenge were 
evaluated histologically for suppurative inflammation and necrosis (Tables 3.8 and 3.9, 
respectively). There was no significant difference in inflammation or necrosis between groups 1-
3. 
Table 3.8 Histopathological analysis-suppurative inflammation 
Group Treatment Suppurative Inflammation1 
  
Prox SC Apex of SC Distal SC 













3/14 8/14 2/14 1/14 5/14 3/14 4/14 2/14 1/14 10/14 2/14 1/14 
4 Strict Control 2/4 2/4 0/4 0/4 0/4 2/4 1/4 0/4 0/4 0/4 2/4 0/4 
1Suppurative Inflammation: “0/None”  (no neutrophilic infiltrates identified), “1/Mild” (multifocal infiltrates of less 
than 10 neutrophils each), “2/Moderate”  (multifocal infiltrates of 10–20 neutrophils each), “3/Severe” (multifocal 
infiltrates of greater than 20 neutrophils each); 2Necrosis: “0/None” (no epithelial necrosis observed), “1/Mild” 
(multifocal necrosis spanning less than 3 crypts), “2/Moderate” (necrosis spanning 3–5 crypts), “3/Severe” (necrosis 




Table 3.9 Histopathological analysis-necrosis 
Group Treatment Necrosis1 
  Prox SC Apex of SC Distal SC 













13/14 0/14 0/14 1/14 12/14 0/14 0/14 2/14 12/14 1/14 0/14 1/14 
4 Strict Control 4/4 0/4 0/4 0/4 4/4 0/4 0/4 0/4 4/4 0/4 0/4 0/4 
1Necrosis: “0/None” (no epithelial necrosis observed), “1/Mild” (multifocal necrosis spanning less than 3 crypts), 
“2/Moderate” (necrosis spanning 3–5 crypts), “3/Severe” (necrosis spanning more than 5 crypts); Values connected 
by different letters in a column are significantly different. 
 
There was no significant difference in the presence of mesocolonic edema or MLN 
abnormality between vaccinated groups that were commingled post-challenge (Groups 1 and 2) 
and the challenge control (Group 3). Between commingled vaccinate groups, however, 
significantly fewer pigs in Group 1 developed mesocolonic edema compared to Group 2 (Mantel-
Haenszel Test, p = 0.0439). See Table 3.10 for mesocolonic edema and mesenteric lymph node by 
group. 
Table 3.10 Mesocolonic edema and mesenteric lymph node 
Group Treatment Mesocolonic Edema Present Enlarged Mesenteric Lymph Node (MLN) 
1 B. hampsonii 30446 PKT 1/11 a 3/11 
2 B. hyodysenteriae B204 PKT 7/14 b 2/14 
3 Challenge Control 5/14 2/14 
4 Strict Control 0/4 1/4 





Group 1 had significantly fewer days of fecal shedding than Group 3 (Mantel-Haenszel 
Test, p = 0.0048) and Group 2 (Mantel-Haenszel Test, p = 0.0028). There were also significantly 
fewer pigs in Group 1 that were ever fecal positive compared to Group 3 (Mantel-Haenszel Test, 
p = 0.0225), and compared to Group 2 (Mantel-Haenszel Test, p = 0.0228). Few pigs in all groups 
were positive for spirochetes by Warthin-Starry (WS) staining on histological sections. See Table 
3.11 for comparison of bacterial culture results by group. Table 3.12 summarizes spirochetes 
detected in the apex of the spiral colon using WS silver staining. 
 
Table 3.11 Brachyspira bacteriological analysis summary 







Culture by One 
or More 
Sample Type 




B. hampsonii 30446 
PKT 
4/11 a 4/11 4/11 4/11 0.73 (0.72) a 
2* 
B. hyodysenteriae B204 
PKT 
12/14 b 3/14 3/14 12/14 2.57 (2.53) b 
3* Challenge Control 12/14 b 6/14 4/14 14/14 2.36 (2.36) b 
4 Strict Control 0/4 0/4 0/4 0/4 0 
* Results reflect the number of samples with recovery of a strongly beta-hemolytic Brachyspira over the number of 
samples tested 







Table 3.12 Spirochetes detected using Warthin-Starry staining in apex of spiral colon 
Group Treatment None Low Moderate High 
1 B. hampsonii 30446 PKT 8/11 1/11 0/11 2/11 
2 B. hyodysenteriae B204 PKT 7/14 3/14 1/14 3/14 
3 Challenge Control 10/14 2/14 0/14 2/14 
4 Strict Control 4/4 0/4 0/4 0/4 
 
Study Criteria 
For the study to be considered valid, strict control animals must not shed strongly beta-
hemolytic Brachyspira in the feces or display MHD throughout the study. All of these conditions 
were met; the study was valid. 
 
Discussion 
As B. hampsonii is a recently described agent of swine dysentery, limited information is 
available regarding the efficacy of vaccines for this agent. To the author’s knowledge, this is the 
first description of a vaccination trial for B. hampsonii. B. hampsonii 30446 was used to make a 
proteinase K vaccine to be used to verify homologous protection. A proteinase K preparation of 
B. hyodysenteriae, the classical agent of swine dysentery, was also included to evaluate potential 
cross protection against a B. hampsonii challenge. In the B .hampsonii Challenge Model (Chapter 
2), all pigs displayed MHD. In the challenge control group (3) of this vaccine efficacy study, a 
majority of pigs (11/14) demonstrated diarrhea (fecal scores ≥2), and only five pigs displayed more 
severe scores (>2) during the post-challenge phase. Based on this, we analyzed the fecal scores 
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using 2 as the cutoff. The change in the study venue between this study and the B. hampsonii 
Challenge Model, the initial illnesses of the pigs, including their antibiotic treatments and removals 
from the study, may have played a role in the lack of challenge severity observed compared to the 
previous study. Previous studies have also suggested that other microorganisms play a vital role in 
Brachyspira infection in pigs, suggesting the antibiotic treatments in this study may have altered 
the clinical severity.49,50 The feed used in both studies was the same so the impact of diet seems 
less likely in this case. The older age at challenge in this study (11-week-old pigs versus 8-week-
old pigs in Chapter 2) may also have reduced the number of animals developing disease in the 
challenge control group as age has been shown to affect disease expression with no pigs 10 weeks 
of age or older developing dysentery versus 100% of 6-week-old pigs in a previous comparison of 
infection models.51 Similarly, in multiple recent B. hampsonii pathogenicity studies12-14,22 pigs 
were 6 to 8 weeks old at the time of inoculation suggesting this may be a more ideal time to 
challenge pigs; however, the timing required for the vaccination phase in the present experiment 
resulted in a later age at challenge. 
The statistical reduction in clinical days and fecal shedding in the B. hampsonii 30446 
proteinase-K vaccine group is promising; however, the cost of preparing this product may limit its 
use as a commercial product. In future studies, this preparation can be used as a reference control 
for efficacy to analyze other potential vaccine candidates. 
The homologous B. hampsonii 30446 proteinase K vaccine resulted in significantly fewer 
clinical days and less fecal shedding compared to the challenge control group. The cross species 
B. hyodysenteriae B204 proteinase K vaccine did not provide notable protection from clinical signs 




 In the future, the Brachyspira proteinase K preparation should be further assessed 
through serological evaluations to determine what proteins are being targeted for antibody 
production in pigs. The western blots from this study suggest that an immune response was 
triggered in the pigs in both the B. hampsonii and B. hyodysenteriae PKT vaccinate groups, but 





CHAPTER 4. SUMMARY AND CONCLUSIONS 
Brachyspira infection models involve many factors including selecting an appropriate 
number of animals in a challenge model. The need for a sufficient number of pigs in each group 
to allow for differences in disease expression that may also provide statistical confidence is 
determined by space, labor resources, and challenge material quantity. The space to hold the pigs 
and the labor required to care for, observe, and sample the pigs depends on funding and site 
availability which are usually variable. The generation of challenge material may also be limited 
to the equipment available for culture generation, but implementing frozen inoculum prepared 
prior to the day of challenge could alleviate this limitation. In Chapter 2, the 30446 fresh and 
frozen groups, determined that while the fresh challenge preparation yielded earlier clinical signs 
and greater duration, the frozen preparation still yielded statistically significant results compared 
to the negative control group. The frozen preparation would allow a larger number of pigs to be 
included in a study, and a more thorough assessment of the challenge material 
(purity/quantification) prior to being administered. Challenge studies have limitations for 
statistical comparison between groups as well due to the inability to show replication of pens.52 
This is due to the need to pen the challenge groups separately in order to prevent cross 
contamination due to Brachyspira shedding. 
In vaccine efficacy studies, the need for a large amount of challenge material would 
increase. Challenge material would have to be provided for both the efficacy group or groups and 
the challenge control group. Clinical observations would be the best-suited parameter to 
determine efficacy. Gross lesion difference may be difficult to observe at the time of necropsy if 
the Brachyspira infection is resolving. In order to discern a difference in clinical signs (mainly 
MHD) between groups in an efficacy study, vaccination needs to be administered early enough 
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in age to provide sufficient time for an immune response while still retaining susceptibility to 
challenge in a large percentage of pigs (<10 weeks of age at challenge). If a vaccine being tested 
also includes a booster, like the vaccine prototypes discussed in Chapter 3, pigs should not be 
older than 3 weeks at first vaccination to ensure clinical signs can be detected during the 
challenge phase. As noted in the efficacy study above, deviations from the original timeline can 
occur due to illness, which leaves little room for timeline adjustments. A live vaccine would also 
result in similar limitations that were mentioned above for the challenge models including the 
inability to show replication of pens due to the inability to commingle pigs in vaccinate groups 
until vaccine shedding was complete. 
The challenges and finances required to run in vivo challenge studies makes ex vivo 
evaluation of challenge isolate candidates attractive.16 More research should be done in this area, 
specifically an in vivo and ex vivo side-by-side evaluation. With more confidence in an ex vivo 
model to evaluate Brachyspira pathogenicity, physiological data could be collected from a 
greater number of time points. If an ex vivo model became more commonplace, it could 
potentially be used to assess attenuated vaccine prototypes to observe their colonization patterns. 
There is currently no known published B. hampsonii efficacy study, specifically 
involving a PKT-digested vaccine prototype. Western blots confirmed that an immune response 
to both B. hampsonii and B. hyodysenteriae vaccines could be detected in the efficacy study 
above. The B. hyodysenteriae vaccine, however, showed a slight reaction to the B. hampsonii-
challenged serum of either study and the group had more severe clinical fecal scores than the 
challenge control group, so proteins that do not provide a protective immune response may also 
be reacting to the serum in the Western Blots. The PKT vaccine method should be considered a 
standard for vaccine testing as it has been shown to be efficacious in both B. hampsonii in this 
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study and B. hyodysenteriae in previous reports.48 Even as a standard, however, there does not 
appear to be significant cross-protection between Brachyspira species. This supports previous 
reports that suggest Brachyspira vaccines may need to have more than one serogroup within a 
species-specific vaccine for protection.1 
Work with B. hyodysenteriae to produce a vaccine prototype that was successful in an 
efficacious animal model is still in progress. Whole cell vaccine attempts for B. hyodysenteriae 
have not shown promising results.53-55 This suggests that an attenuated Brachyspira vaccine that 
colonizes the gut may be required to elicit the desired protective response. A low percentage of 
B. hyodysenteriae isolates have been shown to exhibit avirulent attributes naturally.56 Additional 
vaccine propagation methods have been attempted with B. hyodysenteriae.57,58 While these 
vaccine-candidates show mixed promise, the cross-protection between strains, let alone species, 
has not been successfully demonstrated. The cost of producing these vaccines with a limited 
promise of efficacy also makes them less desirable as vaccine candidates for companies to invest 
in for commercial sale. Encouragingly, in Chapter 3 the PKT B. hampsonii vaccine was effective 
in preventing SD in a homologous challenge model. This suggests parenteral vaccines may be a 
viable solution for this agent and further work is warranted to determine if this vaccine is also 
protective for both clades of B. hampsonii. With the previous B. hyodysenteriae proteinase-
digested vaccine prototypes demonstrating immune response and efficacy against a B. 
hyodysenteriae challenge in pigs, confirming efficacy of a homologous B. hampsonii vaccine 
with this preparation method is promising. Further work can be done to expand our knowledge 
on the immune response elicited in pigs vaccinated with a digest prototype. The durability of this 
vaccine could be evaluated in pigs that are on medicated-feed, and further value could be 
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discovered in pregnant sow studies. If natural passive immunity could be provided to piglets in 
the nursery stage, this could add value in this type of vaccine to the swine industry. 
While the results from Chapter 3 are promising, multiple doses and multiple routes of 
administration are not the only vaccine options for the swine industry. Needleless routes would 
avoid the risk of injection site reactions that may decrease carcass value. In general, a less 
invasive vaccination route (i.e. oral) is preferred by swine managers versus a route that may 
damage the carcass value (i.e. i.m).  
Attenuated oral vaccines would not come without costs, however. While it is beneficial to 
have a vaccine that sheds to ensure that all animals have received the vaccine, the withdrawal 
time could cause some concern. As long as pigs are shedding a Brachyspira species that is 
considered potentially virulent in the field, a confusion can occur if a clinical pig sample is sent 
out to a diagnostic laboratory. Currently available diagnostic tools may not differentiate the 
attenuated vaccine strain from one of the virulent strains which has the potential to add 
significant challenges to Brachyspira monitoring by swine production companies. Accordingly, 
development of a DIVA (differentiating infected from vaccinated animals) vaccine would be 
ideal prior to introduction into the marketplace such that proper diagnostic tools are in place 
before an attenuated live vaccine is launched. Reversion to virulence is another hurdle that a 
modified live vaccine would have to address and need to pass for licensure and sale. 
Additionally, pigs that are in production environments may be receiving in-feed antibiotics for 
other health concerns around the time of optimal vaccination for Brachyspira and thus live 
vaccines may need instructions to avoid use of antibiotics and high doses of heavy metal 
micronutrients during the timeframe of vaccine administration. 
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To set up evaluation of a potential vaccine, the Brachyspira challenge models should also 
be re-evaluated. Dosing in published models can yield approximately 1010 cfu/dose for 3 
consecutive days.59,60 While this heavy dose is effective in inducing disease, it may represent an 
overwhelming dose that is not relevant to field conditions and that no vaccine can overcome. 
Diet and its effects on the intestinal microbiota of pigs during a Brachyspira challenge continues 
to be analyzed.61 In Brachyspira-challenged mice, a low-zinc diet produced more clinical signs.40 
In pigs, chelated zinc was researched as a possible treatment for SD, but did not prove 
effective.62 A study investigating a low-zinc diet in pigs is needed to confirm if the effects seen 
in mice could be reproduced. As seen in mice,63 diets can affect SD clinical signs in pigs, and 
can be used to change the way pigs have been traditionally challenged with Brachyspira.31 Diets 
with altered fiber content,31,60 sorghum-based,64 or with a zinc-inclusion less than 2000 mg/kg65 
can assist in the expression of clinical signs associated with swine dysentery. Diets in challenge 
studies should also avoid feeding chicory roots or inulin as these may reduce disease 
severity.34,66 Diets high in corn starch may also reduce clinical signs in a Brachyspira challenge, 
but more research needs to be done to explore this.67 Furthermore, a high soy diet affected the 
detection rate of Brachyspira in one study,68 but additional research should be done to determine 
the effects of a high soy diet on PCR detection as well as culture detection in inoculated pigs. In 
the context of this information, Brachyspira challenge models with lower doses over fewer days 
could prevent over-challenging pigs in future vaccine efficacy studies. Using a diet that will 
ensure susceptibility to Brachyspira infection in a large percentage of pigs will also aid in this 
effort. In mice and pigs, a reduction from the traditional three dose standard for Brachyspira 
infection models to two doses has already been evaluated and shown effective.10,11 
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Even with the current public pressure to decrease the use of antibiotics in food animals, 
the reality is that site management can only go so far in reducing enteric diseases at large-scale 
facilities. Breaks in biosecurity, and reservoirs of infection such as rodents and waterfowl, are of 
particular concern for Brachyspira infections.1 Any potential vaccine to prevent SD will also 
need to compete with the current efficacious results reported for the antibiotics such as 
tiamulin.22 However, with antibiotic resistance concerns and public pressure to reduce antibiotic 
use in the swine industry, the desire for an efficacious dysentery vaccine will remain present 
within the industry. 
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Sources and Manufacturers 
a. Porcine Brain Heart Infusion Powder, Becton, Dickinson and Co., Franklin Lakes, NJ 
b. GenPure Water System, Thermo Scientific, Waltham, MA 
c. Bio-Shield sterilization Wrap, Cardinal Health, Dublin, OH 
d. AnaeroPack system, Mitsubishi Gas Chemical Co. Inc., Japan 
e. GasPak EZ anaerobe container system, BD Diagnostic Systems, Sparks, MD 
f. Innova44 Incubator, New Brunswick, New Brunswick, NJ 
g. Biotainer, Sigma-Aldrich, St. Louis, MO 
h. Glycerol, Amresco, Solon, OH 
i. Bovine Brain Heart Infusion Powder, Becton, Dickinson and Co., Franklin Lakes, NJ 
j. Sheep Blood Agar, Remel, Lenexa, KS 
k. XLD Agar, Remel, Lenexa, KS 
l. Petroff Hausser Counter, Hausser Scientific, Horsham, PA 
m. Enterisol Ileitis, Boehringer Ingelheim, St. Joseph, MO 
n. Enterisol Salmonella T/C, Boehringer Ingelheim, St. Joseph, MO 
o. CV2SR Agar, Iowa State University Veterinary Diagnostics, Ames, IA 
p. NuPAGE Protein Gel System, Thermo Scientific, Waltham, MA 
q. iBlot 2 Dry Blotting System, Thermo Scientific, Waltham, MA 
r. JMP Pro 14, SAS, Cary, NC 
s. DNeasy Blood and Tissue Kit, Qiagen, Germantown, MD 
t. Draxxin, Zoetis US, Parsippany-Troy Hills, NJ 
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